Medpace Holdings [MEDP] vs Thermo Fisher [TMO] Detailed Stock Comparison
Medpace Holdings
NASDAQ
Loading...
Thermo Fisher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Medpace Holdings wins in 7 metrics, Thermo Fisher wins in 12 metrics, with 0 ties. Thermo Fisher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Medpace Holdings | Thermo Fisher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 34.23 | 28.17 | Thermo Fisher |
| Price-to-Book Ratio | 74.89 | 3.64 | Thermo Fisher |
| Debt-to-Equity Ratio | 86.93 | 69.62 | Thermo Fisher |
| PEG Ratio | 3.15 | 4.96 | Medpace Holdings |
| EV/EBITDA | 25.60 | 19.69 | Thermo Fisher |
| Profit Margin (TTM) | 18.74% | 15.24% | Medpace Holdings |
| Operating Margin (TTM) | 20.94% | 17.84% | Medpace Holdings |
| EBITDA Margin (TTM) | 20.94% | 17.84% | Medpace Holdings |
| Return on Equity | 89.39% | 13.42% | Medpace Holdings |
| Return on Assets (TTM) | 17.09% | 4.97% | Medpace Holdings |
| Free Cash Flow (TTM) | $572.27M | $7.27B | Thermo Fisher |
| Dividend Yield | N/A | 0.31% | N/A |
| 1-Year Return | 15.97% | -20.19% | Medpace Holdings |
| Price-to-Sales Ratio (TTM) | 5.80 | 4.26 | Thermo Fisher |
| Enterprise Value | $12.97B | $213.03B | Thermo Fisher |
| EV/Revenue Ratio | 5.81 | 4.93 | Thermo Fisher |
| Gross Profit Margin (TTM) | 29.84% | 40.61% | Thermo Fisher |
| Revenue per Share (TTM) | $74 | $114 | Thermo Fisher |
| Earnings per Share (Diluted) | $13.46 | $17.31 | Thermo Fisher |
| Beta (Stock Volatility) | 1.43 | 0.75 | Thermo Fisher |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Medpace Holdings vs Thermo Fisher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Medpace Holdings | 2.27% | -1.16% | 46.77% | 53.27% | 33.25% | 35.43% |
| Thermo Fisher | 3.36% | -0.26% | 19.46% | 21.46% | -9.16% | -7.43% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Medpace Holdings | 15.97% | 185.19% | 254.59% | 1,516.76% | 1,516.76% | 1,516.76% |
| Thermo Fisher | -20.19% | -14.18% | 13.97% | 282.36% | 1,020.33% | 1,622.18% |
Performance & Financial Health Analysis: Medpace Holdings vs Thermo Fisher
| Metric | MEDP | TMO |
|---|---|---|
| Market Information | ||
| Market Cap | $12.94B | $184.10B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 335,247 | 2,020,610 |
| 90 Day Avg. Volume | 619,359 | 2,900,827 |
| Last Close | $463.62 | $500.00 |
| 52 Week Range | $250.05 - $501.30 | $385.46 - $627.88 |
| % from 52W High | -7.52% | -20.37% |
| All-Time High | $501.30 (Jul 22, 2025) | $672.34 (Dec 27, 2021) |
| % from All-Time High | -7.52% | -25.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.03% |
| Quarterly Earnings Growth | 0.02% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | 0.15% |
| Operating Margin (TTM) | 0.21% | 0.18% |
| Return on Equity (TTM) | 0.89% | 0.13% |
| Debt to Equity (MRQ) | 86.93 | 69.62 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.15 | $133.77 |
| Cash per Share (MRQ) | $1.65 | $16.92 |
| Operating Cash Flow (TTM) | $614.10M | $7.58B |
| Levered Free Cash Flow (TTM) | $445.14M | $5.18B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.31% |
| Last 12-Month Dividend | N/A | $1.21 |
Valuation & Enterprise Metrics Analysis: Medpace Holdings vs Thermo Fisher
| Metric | MEDP | TMO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 34.23 | 28.17 |
| Forward P/E | 36.88 | 20.76 |
| PEG Ratio | 3.15 | 4.96 |
| Price to Sales (TTM) | 5.80 | 4.26 |
| Price to Book (MRQ) | 74.89 | 3.64 |
| Market Capitalization | ||
| Market Capitalization | $12.94B | $184.10B |
| Enterprise Value | $12.97B | $213.03B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.81 | 4.93 |
| Enterprise to EBITDA | 25.60 | 19.69 |
| Risk & Other Metrics | ||
| Beta | 1.43 | 0.75 |
| Book Value per Share (MRQ) | $6.15 | $133.77 |
Financial Statements Comparison: Medpace Holdings vs Thermo Fisher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MEDP | TMO |
|---|---|---|
| Revenue/Sales | $558.57M | $10.36B |
| Cost of Goods Sold | $380.22M | $6.13B |
| Gross Profit | $178.35M | $4.24B |
| Research & Development | N/A | $342.00M |
| Operating Income (EBIT) | $113.52M | $1.82B |
| EBITDA | $120.45M | $2.73B |
| Pre-Tax Income | $118.17M | $1.62B |
| Income Tax | $3.58M | $95.00M |
| Net Income (Profit) | $114.60M | $1.51B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MEDP | TMO |
|---|---|---|
| Cash & Equivalents | $441.44M | $4.13B |
| Total Current Assets | $821.44M | $23.38B |
| Total Current Liabilities | $1.12B | $13.17B |
| Long-Term Debt | $126.66M | $31.37B |
| Total Shareholders Equity | $593.61M | $49.49B |
| Retained Earnings | $-269.72M | $54.45B |
| Property, Plant & Equipment | $258.19M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MEDP | TMO |
|---|---|---|
| Operating Cash Flow | $166.55M | $2.15B |
| Capital Expenditures | $-9.99M | $-350.00M |
| Free Cash Flow | $115.84M | $361.00M |
| Debt Repayment | N/A | $-838.00M |
| Common Stock Repurchase | $-371.90M | $-2.00B |
Short Interest & Institutional Ownership Analysis
| Metric | MEDP | TMO |
|---|---|---|
| Shares Short | 2.50M | 3.71M |
| Short Ratio | 3.60 | 1.14 |
| Short % of Float | 0.11% | 0.01% |
| Average Daily Volume (10 Day) | 335,247 | 2,020,610 |
| Average Daily Volume (90 Day) | 619,359 | 2,900,827 |
| Shares Outstanding | 30.63M | 380.77M |
| Float Shares | 22.22M | 376.76M |
| % Held by Insiders | 0.21% | 0.00% |
| % Held by Institutions | 0.96% | 0.92% |
Dividend Analysis & Yield Comparison: Medpace Holdings vs Thermo Fisher
| Metric | MEDP | TMO |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.21 |
| Last 12-Month Dividend Yield | N/A | 0.31% |
| 3-Year Avg Annual Dividend | N/A | $1.33 |
| 3-Year Avg Dividend Yield | N/A | 0.07% |
| 3-Year Total Dividends | N/A | $3.99 |
| Ex-Dividend Date | N/A | Mar 14, 2025 |